INTELGENX RECEIVES USPTO NOTICE OF ALLOWANCE FOR MONTELUKAST ORANGE BOOK ELIGIBLE PATENT
December 11, 2017
SAINT-LAURENT, QUEBEC -- (Marketwired) -- 12/11/17 -- IntelGenx Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) ("IntelGenx"), a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform, today announced that the United States Patent and Trademark Office ("USPTO") has granted a Notice of Allowance for US Patent Application 15/299,054, entitled "Device and Method of Treating Conditions Associated with Neuroinflammation." This film formulation patent covers Montelukast oral film formulations designed for the treatment of neuroinflammation and is intended to protect IntelGenx' Montelukast VersaFilm™ product.
IntelGenx' new, soon to be patented Montelukast oral film technology is designed to provide increased plasma concentration as compared with an immediate release oral tablet having an identical loading of Montelukast.
"The granting of this notice of allowance for a formulation specific orange book eligible patent for our Montelukast oral film validates the innovative work carried out on this project by our talented R&D team" said Horst G. Zerbe, CEO of IntelGenx. "While expanding our overall intellectual property portfolio, this new patent also solidifies the potential long-term market exclusivity of our unique Montelukast film product."
IntelGenx has several additional Montelukast-specific patent applications pending at the USPTO and foreign patent offices in relation to its proprietary Montelukast VersaFilm™ technology.
